Are all 5-HT3 receptor antagonists the same?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 1, 2007, Pages 35-43

  McNulty, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Dolasetron; Granisetron; Nausea; Ondansetron; Palonosetron; Vomiting

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTINEOPLASTIC AGENT; APREPITANT; BLEOMYCIN; CARBONYL REDUCTASE; CISPLATIN; CORTICOSTEROID; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DELTA OPIATE RECEPTOR; DEXAMETHASONE; DOLASETRON MESILATE; ETOPOSIDE; GRANISETRON; HYDRODOLASETRON; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; MUSCARINIC M2 RECEPTOR; ONDANSETRON; PALONOSETRON; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; STEROID;

ARTICLE; BINDING AFFINITY; BLURRED VISION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEADACHE; HUMAN; HYDROXYLATION; MEDICAL PRACTICE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NONHUMAN; PRACTICE GUIDELINE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SYSTEMATIC REVIEW; TESTIS CANCER; TREATMENT RESPONSE;

EID: 33846847899     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0005     Document Type: Article

References (51)

1. Ettinger DS, Bierman PJ, Bradbury B, et al. The NCCN antiemesis clinical practice guidelines in oncology, version 2, 2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed July 30, 2006.
2. Kris MG, Hesketh PJ, Somerfield, MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2946.
3. Cancer Care Ontario: use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy, 2003. Available at: http://www.cancercare.on.ca/pdf/pebc12_3f.pdf. Accessed October 28, 2006.
4. Forni C, Ferrari S, Loro L, et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer 2000;8:131-133.
5. Barrajon E, de las Penas R. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis. Support Care Cancer 2000;8:323-333.
6. Gralla RJ, Navari RM, Hesketh PJ, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998;16:1568-1573.
7. Poon RT, Chow LW. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. Br J Cancer 1998;77:1683-1685.
8. Perez EA, Lembersky B, Kaywin P, et al. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1998;4:52-58.
9. Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754-760.
10. Italian Group of Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995;6:805-810.
11. Stewart A, McQuade B, Cronje JD, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology 1995;52:202-210.
12. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 1995;13:1242-1248.
13. Huc P, Block S, Carlier D, et al. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord]. Bull Cancer 1998;85:562-568 [in French].
14. Jantunen IT, Muhonen TT, Kataja VV, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer 1993;29A:1669-1672.
15. Fox-Geiman MP, Fisher SG, Kiley K, et al. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 2001;7:596-603.
16. Spitzer TR, Friedman CJ, Bushnell W, et al. Double blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000;26:203-210.
17. Orchard PJ, Rogosheske J, Burns L, et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 1999;5:386-393.
18. Slaby J, Trneny M, Prochazka B, et al. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 2000;47:319-322.
19. Walsh T, Morris AK, Holle LM, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant 2004;34:963-968.
20. Lacerda JF, Martins C, Carmo JA, et al. Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting. Transplant Proc 2000;32:2680-2681.
21. Bonneterre J, Hecquet B. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer 1995;82:1038-1043.
22. Martoni A, Angelelli B, Guaraldi M, et al. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer 1996;32A:82-85.
23. Park JO, Rha SY, Yoo NC, et al. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol 1997;20:569-572.
24. Mantovani G, Maccio A, Curreli L, et al. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep 1998;5:273-280.
25. Chiou TJ, Tzeng WF, Wang WS, et al. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Zhonghua Yi Xue Za Zhi (Taipei) 2000;63:729-736.
26. Chua DT, Sham JS, Kwong DL, et al. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Am J Clin Oncol 2000;23:185-191.
27. Oge A, Alkis N, Oge O, et al. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin. J Chemother 2000;12:105-108.
28. Yalcin S, Tekuzman G, Baltali E, et al. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am J Clin Oncol 1999;22:94-96.
29. Gibbs SJ, Cassoni AM. A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation. Clin Oncol (R Coll Radiol) 1996;8:182-184.
30. Kalaycio M, Mendez Z, Pohlman B, et al. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J Cancer Res Clin Oncol 1998;124:265-269.
31. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 1994;74:1945-1952.
32. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994;51:113-118.
33. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer 1994;30A:1083-1088.
34. Jaing TH, Tsay PK, Hung IJ, et al. Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide- based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2004;21:227-235.
35. Zeidman A, Ben Dayan D, Ben Zion T, et al. Granisetron and ondansetron for chemotherapy-related nausea and vomiting. Haematologia (Budap) 1998;29:25-31.
36. Herrington JD, Kwan P, Young RR, et al. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy 2000;20:1318-1323.
37. Farley PA, Dempsey CL, Shillington AA, et al. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health Syst Pharm 1997;54:2478-2482.
38. Dempsey CL, Coop AJ, Shillington A, et al. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health Syst Pharm 2004;61:781-786.
39. de Wit R, de Boer AC, vd Linden GH, et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001;85:1099-1101.
40. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer 1996;32A:1523-1529.
41. Tan M, Xu R, Seth R. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study. Curr Med Res Opin 2004;20:879-882.
42. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-813.
43. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-Induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-Induced Emesis Prevention Group. J Clin Oncol 1996;14:2242-2249.
44. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966-2973.
45. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
46. Aapro MS, Grunberg, SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449.
47. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482.
48. del Giglio A, Soares HP, Caparroz C, et al. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301-2308.
49. Hunt TL, Gallagher SC, Cullen MT Jr, et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J Clin Pharmacol 2005;45:589-596.
50. Brames MJ, Roth BJ, Dreicer R, et al. Palonosetron + dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin for germ cell cancer. Presented at the 42nd annual meeting of the American Society of Clinical Oncology. Atlanta, Georgia, June 2-6, 2006.
51. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-2811.